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Summary
Prions are unconventional infectious agents respon-
sible for transmissible spongiform encephalopathy
(TSE) diseases. They are thought to be composed ex-
clusively of the protease-resistant prion protein
(PrPres) that replicates in the body by inducing the
misfolding of the cellular prion protein (PrPC). Al-
though compelling evidence supports this hypothe-
sis, generation of infectious prion particles in vitro
has not been convincingly demonstrated. Here we
show that PrPC/ PrPres conversion can be mimicked
in vitro by cyclic amplification of protein misfolding,
resulting in indefinite amplification of PrPres. The
in vitro-generated forms of PrPres share similar bio-
chemical and structural properties with PrPres derived
from sick brains. Inoculation of wild-type hamsters
with in vitro-produced PrPres led to a scrapie disease
identical to the illness produced by brain infectious
material. These findings demonstrate that prions can
be generated in vitro and provide strong evidence in
support of the protein-only hypothesis of prion trans-
mission.
Introduction
Prion diseases, also called transmissible spongiform
encephalopathies (TSEs), are some of the most intrigu-
ing infectious disorders affecting the brains of humans
and animals. The group is comprised of Creutzfeldt-
Jakob disease (CJD), kuru, Gerstmann-Sträussler Shein-
ker syndrome (GSS), and fatal familial insomnia (FFI) in
humans and scrapie, bovine spongiform encephalopa-
thy (BSE), and chronic wasting disease (CWD) in ani-
mals (Collinge, 2001). TSEs can have sporadic, inher-
ited, and infectious origins. The nature of the
transmissible agent has been the subject of intense de-
bate (Prusiner, 1998; Mestel, 1996; Chesebro, 1998;
Soto and Castilla, 2004). Initially the agent was thought
to be a slow virus (Sigurdsson, 1954), but further re-
search has indicated that the infectious particle is sig-
nificantly different from viruses and other conventional*Correspondence: clsoto@utmb.eduagents (Prusiner, 1998). Accordingly, a new hypothesis
regarding the nature of the transmissible agent has
emerged and recently gained widespread acceptance.
This hypothesis proposes that the material responsible
for the disease transmission is uniquely composed of
a protein that has the surprising ability to replicate itself
within the body (Prusiner, 1982; Prusiner, 1998). This
newly discovered pathogen is called a proteinaceous
infectious particle, or prion (Prusiner, 1982).
An important step in understanding the nature of this
novel infectious agent was the isolation of the prote-
ase-resistant prion protein (PrPres) from the infectious
material (Bolton et al., 1982). Using biochemical and im-
munological methods, it was shown that PrPSc and in-
fectivity copurified and that the concentration of the
protein was proportional to the infectivity titer (Gabizon
et al., 1988). Infectivity was retained in highly purified
preparations of PrPres, in which no other component
is detectable. In addition, infectivity was convincingly
reduced by agents that destroy protein structure and
by anti-PrP antibodies (Gabizon et al., 1988). Purifica-
tion of PrP led to the identification of the gene contain-
ing the sequence that encodes PrP (Basler et al., 1986).
PrP mRNA is the product of a single gene that is syn-
thesized in the brains of healthy animals and is also
constitutively expressed in many cell types (Basler et
al., 1986). Thus, PrP has two alternate forms: the nor-
mal cellular protein (PrPC) and the pathological isoform
(PrPres). Chemical differences between the PrPC and
PrPres isoforms have not been detected (Stahl et al.,
1993), and the conversion seems to involve a confor-
mational change in which the α-helical content of the
normal protein is reduced while the β sheet content is
increased (Pan et al., 1993). Structural changes are ac-
companied by alterations in the biochemical properties
(Prusiner, 1998; Cohen and Prusiner, 1998). As such,
PrPC is soluble in nondenaturing detergents while
PrPres is insoluble, and PrPC is readily digested by pro-
teases while PrPres is mostly resistant, resulting in the
formation of an N-terminally truncated fragment known
as PrP27–30.
The structural conversion of PrPC into PrPres cata-
lyzed by PrPres has been done in vitro. The cell-free
conversion system developed by Caughey and cowork-
ers (Kocisko et al., 1994) using purified PrPC mixed with
stoichiometric amounts of purified PrPres produced a
low yield of PrPres formation under nonphysiological
conditions, making it difficult to evaluate the infectious
properties of in vitro-produced misfolded protein. How-
ever, the fact that PrPres was able to induce the trans-
formation of the normal protein into more of itself repre-
sented important evidence in favor of the prion
hypothesis. More recently, we developed a new in vitro
conversion system to convert large quantities of PrPC
into PrPres using minute amounts of PrPres (Saborio et
al., 2001). This system, called PMCA (protein misfolding
cyclic amplification), confirms a central facet of the
prion hypothesis, which is that prion replication is a cy-
clical process and that newly produced PrPres can fur-
ther propagate the protein misfolding (Soto et al., 2002).
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196Figure 1. Infinite PrPres Replication In Vitro by Serial PMCA
(A) Hamster scrapie brain homogenate was diluted 104-fold into normal brain homogenate and subjected to 20 cycles of PMCA as described
in Experimental Procedures. The amplified material was diluted 10-fold into normal brain homogenate and amplified again. This procedure
was repeated several times to reach a 10−20 dilution of scrapie brain homogenate. Mathematical estimations indicate that the last molecule
of PrPres from the inoculum was lost at the 10−14 dilution.
(B) PrPres samples from the 10−20 dilution were further replicated up to 10−40 by serial PMCA after 100-fold dilutions followed by 48 PMCA
cycles.
(C) PrPres samples from the 10−40 dilution were further replicated to reach a 10−55 dilution by performing 48 PMCA cycles and 1000-fold
dilutions of the samples. F, frozen samples; A, amplified samples.The PMCA technology was experimentally designed to s
Smimic some of the fundamental steps involved in PrPres
replication in vivo at an accelerated rate (Soto et al., a
t2002). In a cyclic manner conceptually analogous to
PCR cycling, a minute quantity of PrPres is incubated a
vwith excess PrPC to enlarge the PrPres aggregates that
are then sonicated to generate multiple smaller units 2
for the continued formation of new PrPres (Saborio et
al., 2001). A modest level of amplification has also been c
eobserved without sonication (Saborio et al., 2001; Lu-
cassen et al., 2003; Deleault et al., 2003), and the extent P
mof conversion depends upon the number of PMCA cy-
cles (Saborio et al., 2001; Bieschke et al., 2004; Piening t
pet al., 2005).
In spite of the compelling evidence supporting the p
cprion hypothesis, there is still considerable skepticism
among scientists (Chesebro, 1998; Mestel, 1996; Soto w
hand Castilla, 2004). It is widely accepted that the prion
hypothesis can ultimately only be proven once infectiv- t
hity can be generated in a test tube. If the infectious
agent is misfolded PrPres and its replication is pro- t
cmoted by interaction with PrPC, then it should be pos-ible to reproduce the whole process entirely in vitro.
everal strategies have been employed to achieve this
im, but all have failed or have produced infectivity af-
er a very long time of incubation and only in transgenic
nimals highly overexpressing mutated or truncated
ersions of PrP (May et al., 2004; Soto and Castilla,
004; Legname et al., 2004).
The aim of this study was to evaluate the biochemi-
al, structural, and infectious properties of in vitro-gen-
rated PrPres. For this purpose we have optimized the
MCA procedure to produce high levels of PrPres for-
ation in vitro and developed the conditions to main-
ain PrPres indefinitely propagating in vitro at the ex-
ense of PrPC with the goal of producing misfolded
rotein free from brain PrPres inoculum. Our results indi-
ate that PrPres generated in vitro under conditions in
hich no brain-derived PrPres is present in the sample
as the same structural and biochemical properties as
he disease-associated protein. More importantly, we
ave shown that the PMCA-generated protein is infec-
ious to wild-type animals, leading to a disease that has
linical, histological, and biochemical properties that
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197are identical to the illness produced by the prion infec-
tious agent. These findings represent the first time that
wild-type animals have been infected with PrPres gener-
ated in vitro and thus constitute some of the strongest
evidence yet available supporting the prion hypothesis.
Results
Infinite Replication of PrPres In Vitro
Hamster brains infected with 263K scrapie were ho-
mogenized and diluted 104-fold into a 10% normal
hamster brain homogenate. Samples were either imme-
diately frozen or subjected to 20 PMCA cycles. After
this first round of PMCA, a small aliquot of the amplified
samples was taken and diluted 10-fold into more nor-
mal brain homogenate. These samples were again im-
mediately frozen or amplified by 20 PMCA cycles. This
procedure was repeated several times, and PrPres gen-
eration was determined by Western blot after protein-
ase K (PK) digestion to remove the remaining PrPC. Fig-
ure 1A shows the results of an experiment in which 17
rounds of PMCA were performed. In the final series of
PMCA, the amount of scrapie brain homogenate is
equivalent to a 1020-fold dilution. Estimation of the
amount of PrPres inoculum present indicates that after
this dilution no molecules of brain-derived protein were
present, whereas the amount of newly generated PrPres
corresponds to approximately 1 × 1011 molecules. The
amplified samples for the 10−20 dilution were further di-
luted and subjected to several rounds of PMCA sepa-
rated by 100-fold dilutions to reach a final dilution of
scrapie brain homogenate equivalent to 10−40 (Figure
1B). The serial replication of PrPres was additionally
continued up to a 10−55 dilution by performing a series
of 1000-fold dilutions followed by 48 cycles of PMCA
(Figure 1C). We conclude from these results that PMCA
enables an infinite replication of PrPres in vitro. Interest-
ingly, the signal can be fully recovered even after 1000-
fold dilution of the sample, suggesting that the amplifi-
cation rate is at least 1000. Moreover, the rate of PrP
replication was not altered upon dilution, which sug-
gests that newly converted protein is capable of induc-
ing PrPres formation with an efficiency similar to that of
brain-derived PrPres. A control experiment in which the
healthy brain homogenate was serially diluted into itself
and subjected to the same number of PMCA cycles as
described above but in the absence of PrPres inoculum
did not show any protease-resistant PrP under any
conditions (data not shown).
Biochemical and Structural Properties
of In Vitro-Generated PrPres
An in vitro-generated PrPres sample that does not con-
tain any brain-derived PrPres provides an ideal material
for analyzing the biochemical and structural properties
of the in vitro-produced protein and comparing them
with the properties of in vivo-generated PrPres. A first
comparison using Western blot profiles indicates that
in vitro replication leads to a protein with identical
electrophoretic mobility and glycosylation pattern tothe disease-associated misfolded protein (Figure 2A).
Indeed, experiments using PrPres inoculum from dif-
ferent species/strains with distinct Western blot pro-
files showed that newly generated PrPres always fol-
lows the pattern of the misfolded protein used as
template (Soto et al., 2005). Furthermore, amino acid
composition analysis of highly purified PrPres produced
in vitro shows very similar results to those found using
brain-derived PrPres (data not shown), indicating that
the cleavage site after PK digestion is the same in both
proteins. This is important because PrPres from different
strains has been shown to have a distinct PK cleavage
site due to the different folding or aggregation of the
protein (Chen et al., 2000; Collinge et al., 1996). The
similar glycosylation pattern of newly generated and
brain-derived PrPres was further confirmed in experi-
ments in which the proteins were treated with endogly-
cosidase (Figure 2A). The results demonstrate that the
enzymatic removal of glycosylated chains occurs with
similar efficiency in both proteins and that the unglyco-
sylated bands have the same molecular weight.
A typical feature of misfolded PrP that has been
extensively used to distinguish it from the normal pro-
tein isoform is the high resistance of the pathological
protein to protease degradation. To compare the pro-
tease-resistance profile, similar quantities of PMCA-
generated PrPres (produced after a 10−20 dilution of
scrapie brain homogenate) and brain-derived PrPres
were treated for 60 min with 50, 100, 150, 200, 250,
1,000, 2,500, 5,000 and 10,000 g/ml of PK (Figure 2B).
Both proteins were highly resistant to these large PK
concentrations, and, strikingly, the pattern of resistance
was virtually identical. This result is very significant be-
cause protease resistance is one of the hallmark prop-
erties of disease-associated PrP, and its quantity corre-
lates tightly with infectivity (McKinley et al., 1983).
Several procedures have been reported to produce
protease-resistant forms of PrP, but in most of these
cases the protease resistance was only detected at low
concentrations of the enzyme and was thus not compa-
rable to the extent of protease resistance seen in bona
fide PrPres (Jackson et al., 1999; Lehmann and Harris,
1996; Lee and Eisenberg, 2003).
Another typical property of misfolded PrP is its high
insolubility in nonionic detergents. More than 95% of
PrPres derived both from brain and from PMCA was de-
tected in the pellet after incubation and centrifugation
in the presence of 10% sarkosyl, indicating that the two
proteins are highly and similarly insoluble (Figure 3A).
Insolubility of PrPres was lost when the proteins were
treated with >2 M guanidine hydrochloride, indicating
that PrPres from both origins was equally sensitive to
denaturation by a chaotropic agent (Figure 3B).
The main difference between PrPC and PrPres, which
is responsible for the other biochemical distinctions, is
the secondary structure of the two proteins: whereas
PrPC is mainly α-helical, PrPres is rich in β sheet confor-
mation (Pan et al., 1993; Cohen and Prusiner, 1998). To
study the secondary structure, PrPres was highly puri-
fied from the brain of scrapie-sick hamsters or from
samples amplified after a 10−20 dilution, as described
in Figure 1. The standard purification procedure based
on differential precipitation in detergents and protease
degradation was used, and purity was estimated to be
Cell
198Figure 2. Electrophoretic Pattern, Deglyco-
sylation, and Protease-Resistance Proper-
ties of In Vitro-Generated PrPres
(A) Aliquots containing similar quantities of
brain-derived PrPres and the misfolded pro-
tein obtained by PMCA after a 10−20 dilution
of scrapie brain homogenate (as shown in
Figure 1A) were subjected to proteinase K
(PK) digestion (50 g/ml for 60 min) and
loaded onto SDS-PAGE. Immunoreactive
bands were observed using Western blot
and a 3F4 monoclonal antibody. Similar ali-
quots of both proteins were subjected to de-
glycosylation by treatment with peptide
N-glycosidase F for 2 hr at 37°C. Western
blot analyses of different dilutions before
and after deglycosylation were performed.
(B) Aliquots of PrPres generated in vitro after
a 10−20 dilution of brain PrPres or misfolded
protein obtained from scrapie brain homoge-
nate were incubated for 60 min at 45°C, with
the indicated concentrations of PK and
PrPres signal being detected by Western blot
analysis as described in Experimental Pro-
cedures.microscopy after negative staining. Both proteins makea drawback for most of the in vitro PrP refolding assays
Figure 3. Detergent Solubility Studies
(A) Samples containing PMCA-generated or
brain-derived PrPres in 10% sarkosyl (final
concentration) were centrifuged at 100,000 ×
g for 1 hr at 4°C, and the pellet (P) and super-
natant (S) were treated with PK. PrP signal
was detected using Western blotting. The
distribution of PrPC not treated with PK is
shown as a control.
(B) Samples of PrPres produced in vitro and
in vivo were treated with the indicated con-
centrations of guanidine hydrochloride for
2 hr and thereafter centrifuged as described
earlier. PrPres in the pellet was detected by
Western blot after PK digestion.>90% by silver staining after electrophoresis and by i
namino acid composition analysis. Structural studies
conducted using Fourier transform infrared (FTIR) 2
tspectroscopy of in vitro-generated PrPres showed a
spectrum consisting of high levels of β sheet content e
ithat was very similar to the spectrum obtained for puri-
fied brain-derived PrPres (Figure 4). Deconvolution and h
pfitting analysis of the spectra showed a virtually iden-
tical profile of secondary structures for both proteins <
(Figure 4), which are consistent with those previously
reported for hamster PrPres (Caughey et al., 1998; Pan i
iet al., 1993). Importantly, the spectra show a still rela-
tively high content of α-helical structure, as expected 1
afor disease-associated misfolded prion protein (May et
al., 2004). The lack of α-helical structure is considered an which the PrPres-like form is almost entirely orga-
ized in an aggregated β sheet structure (May et al.,
004). The high levels of β sheet structure, as well as
he presence of random coil and α helix for PMCA-gen-
rated PrPres, were also confirmed by circular dichro-
sm studies. FTIR spectra of recombinant full-length
amster PrPC produced in bacteria showed the ex-
ected high proportion of α helix and random coil and
10% of β sheet structure (data not shown).
The high content of β sheet structure of PrPres results
n a high tendency to form larger-order aggregates
n vitro and in vivo (Prusiner et al., 1983; Ghetti et al.,
996). To study the ultrastructural characteristics of the
ggregates, samples from highly purified brain-derived
nd PMCA-generated PrPres were analyzed by electron
Production of Prion Infectivity In Vitro
199Figure 4. Secondary Structure of PMCA-Generated and Brain-
Derived PrPres
Samples of highly purified PrP27–30 (5 mg/ml in phosphate-buf-
fered saline) obtained from PrPres generated in vitro after a 10−20
dilution of brain PrPres or from 263K scrapie hamster brain were
loaded into Fourier transform infrared spectroscopy cuvettes and
dried by passing a flow of nitrogen. Fourier self-deconvolution and
curve fitting of the amide I region of the spectra was done using
the Grams software. The table shows the estimation of the percen-
tage of different secondary-structure motifs.typical prion rod-like structures that are 10 to 20 nm in
diameter and 50 to 100 nm in length (Figure S1), as
previously described (Prusiner et al., 1983; Wille et al.,
2000).
A hallmark property of prions is their capability to
sustain autocatalytic replication in vivo (Prusiner, 1998).
Injection of brain extracts containing PrPres into an ani-
mal can further direct the conversion of normal PrPC,
and the misfolded protein can in this way keep replicat-
ing across animals and generations (Prusiner, 1998).
The results shown in Figure 1 suggest that newly
formed PrPres is able to maintain replication in vitro
even in the absence of brain-derived PrPres. However,
in order to analyze whether the efficiency of conversion
is the same, we compared the rate of PrPC conversion
induced by brain-derived and PMCA-produced PrPres.
For these experiments, aliquots of both samples con-
taining a similar amount of PrPres equivalent to a 100-
fold dilution of scrapie brain homogenate were further
diluted into normal brain homogenate and subjected to
20 amplification cycles. As shown in Figure 5A, bothsamples were able to convert high levels of PrPC to
produce a similar amount of PrPres. The efficient con-
version was lost under these conditions when the sam-
ples were diluted more than 160-fold (16,000-fold in to-
tal). This result indicates that an approximately 300-fold
amplification rate was obtained for both brain and
PMCA PrPres using 20 amplification cycles (Figure 5A).
As described before, the rate of amplification depends
upon the number of cycles performed (for example, a
>6500-fold amplification was obtained when samples
were subjected to 140 cycles), but, again, this rate was
similar regardless of whether PrPres came from in vivo
brain samples or from in vitro-produced protein (data
not shown).
Finally, we studied whether the converting activity of
in vitro-generated PrPres is as resistant to denaturation
as has been reported for brain PrPres. Samples of brain-
derived and in vitro-generated PrPres were subjected
to thermal denaturation by incubation at 100°C, 110°C,
120°C, and 140°C for 1 hr. Thereafter, these samples
were used to trigger PrPres formation by diluting them
into normal brain homogenate and performing 20
PMCA cycles. Generation of new PrPres was not altered
by previously heating the samples at 100°C or 110°C,
but this activity was dramatically reduced by incubating
PrPres at 120°C and completely abolished after heating
at 140°C (Figure 5B). Interestingly, the heat-resistance
profile of both brain-derived and PMCA-produced
PrPres was very similar, further supporting the hypothe-
sis that the two forms resemble each other.
PrPres Generated In Vitro Is Infectious
One objective that has long been pursued is the in vitro
production of prion infectious material by inducing the
misfolding of PrP. Successful completion of this experi-
ment is widely regarded as the final proof for the con-
troversial protein-only hypothesis of prion propagation
(Soto and Castilla, 2004). The serial replication of PrPres
in vitro by PMCA provides a perfect system to achieve
this aim because, after many rounds of amplification
following serial dilution of PrPres inoculum, we were
able to produce a preparation of misfolded protein that
was biochemically and structurally identical to brain-
derived PrPres but lacked any molecules of the initial
scrapie-infected inoculum. To determine the infectious
capability of in vitro-generated PrPres, groups of wild-
type Syrian hamsters were inoculated intracerebrally
(i.c.) with samples generated by 6 or 16 rounds of serial
PMCA separated by 10-fold dilutions as described in
Figure 1 (see Figure S2 for a schematic description of
the groups used in this study). Since at the first PMCA
the dilution of scrapie brain homogenate was 10−4, the
final dilution of scrapie material in these groups corres-
ponds to 10−9 and 10−19, respectively. An additional 10-
fold dilution in phosphate-buffered saline was per-
formed in all samples before inoculation. As shown in
Figure 1, despite the large dilution, the quantity of
PrPres remained constant after amplification. Detailed
estimation by quantitative Western blot analysis indi-
cated that the amount of PrPres in these samples was
similar to the quantity of PK-resistant protein present
in a 10−4 dilution of 263K hamster brain, which contains
approximately 1010 molecules of the misfolded protein.
Cell
200Figure 5. Self-Propagation and Heat Inacti-
vation of PrPres
(A) The efficiency with which PMCA-gener-
ated PrPres induced the conversion of PrPC
in vitro was compared to the rate of conver-
sion induced by brain-derived PrPres. For
this purpose, small and equivalent aliquots
of both proteins (lane 1, I) were diluted 20-,
40-, 80-, 160-, and 320-fold into normal brain
homogenate and subjected to 20 cycles of
PMCA. The formation of newly generated
PrPres was determined using Western blot
analysis.
(B) The resistance of PrPres from both origins
to heat inactivation was determined by incu-
bating equivalent aliquots of the proteins at
the indicated temperatures for 20 min.
Thereafter, the samples were diluted 100-
fold into normal brain homogenate and
tested for their ability to induce the conver-
sion of normal PrPC into the protease-resis-
tant isoform using 20 cycles of PMCA. F: fro-
zen samples; A: amplified samples.In the animals infected with the 10−10 dilution (group 6
min Table 1), 99.99999% of this material corresponded to
newly generated PrPres (0.99999 × 1010 molecules) and s
ionly 0.000001% to brain-derived PrPres (1 × 104 mole-
cules). In the 10−20 dilution (group 7), 100% of PrPres T
1was newly generated protein (1 × 1010 molecules).
Strikingly, all of the animals in these two sets (groups 6 e
rand 7) showed typical signs of scrapie and died of the
disease at around 170 days after inoculation (Table 1). 1, 2, 3, and 4). Two different negative control groups
Table 1. Infectivity Associated with In Vitro-Generated PrPres
Predicted Survival Observed Survival Time
Scrapie Brain Molecules of PrPres Time (% Sick (Number of Sick/Total
Group Experimental Condition Dilution (Brain/PMCA) Animals) Animals)
1 Negative control: SBH 10−10 w104 (104/0) >600 days (0%) >400 days (0/6)
diluted in NBH
nonamplified
2 Negative control: SBH 10−20 0 (0/0) >600 days (0%) >400 days (0/6)
diluted in NBH
nonamplified
3 Negative control: SBH 10−10 w104 (104/0) >600 days (0%) >400 days (0/6)
diluted in null BH
amplified
4 Negative control: SBH 10−20 0 (0/0) >600 days (0%) >400 days (0/6)
diluted in null BH
amplified
5 Positive control: SBH 10−4 w1010 (1010/0) 94 ± 2.7 days (100%) 106 ± 2.9 days (6/6)
diluted in NBH
nonamplified
6 Experiment: SBH diluted in 10−10 w1010 (104/0.99 × 1010) ? 177 ± 7.3 days (6/6)
NBH amplified
7 Experiment: SBH diluted in 10−20 w1010 (0/1010) ? 162 ± 3.5 days (6/6)
NBH amplified
The number of molecules of PrPres were estimated based on quantitative Western blot, using known concentrations of recombinant hamster
PrP as standard. The predicted survival times are based on our previous data as well as published observations. Observed survival time is
expressed as average ± standard error.Based on our experience with the 263K experimental
odel and the literature reports, the 10−9 dilution of
crapie brain homogenate is the last dilution in which
nfectivity is observed (and only in some animals).
herefore, we hypothesized that dilutions equivalent to
0−10 and 10−20 would not produce any detectable dis-
ase (Table 1). This estimation was confirmed by the
esults obtained in our control groups (Table 1; groups
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tions of the scrapie brain homogenate into normal ham-
ster brain homogenate done in serial 10-fold dilutions
in parallel to the samples for PMCA but kept frozen
without amplification (groups 1 and 2). The second con-
trol consisted of the scrapie brain homogenate diluted
serially into PrP-knockout mouse brain homogenate up
to 1010- and 1020-fold dilutions and subjected to the
PMCA cycling (groups 3 and 4) in the same way as the
study samples. None of the animals in these four
groups of negative control samples had shown any
signs of disease up to 400 days after infection (Table
1). This result clearly indicates that infectivity seen in
the PMCA-amplified samples is associated with newly
in vitro-generated PrPres.
To compare the infectious capacity of PMCA-pro-
duced PrPres with brain-derived infectivity, a group of
animals were inoculated with a sample containing a
similar amount of PrPres as the ones produced after 6
and 16 serial PMCA rounds. As mentioned above, care-
ful estimation using Western blot analysis showed that
the quantity of PrPres after the serial PMCA assays was
equivalent to a 10−3 dilution of scrapie brain homoge-
nate (10−4 considering the further 10-fold dilution prior
to inoculation). A positive control group of animals
(group 5) injected with this dilution of scrapie brain de-
veloped the disease with a mean survival time of 106
days (Table 1). The material for this experiment and the
dilution used correspond exactly to the sample utilized
to begin PMCA amplification, so it serves as the double
control of the infectivity present in the sample prior to
any dilution and amplification as well as the infectivity
associated with this amount of PrPres. The survival time
was shorter than the one obtained with the equivalent
quantity of PMCA-generated PrPres, indicating that the
in vitro-generated misfolded protein was significantly
less infectious. We are currently doing infectivity titra-
tion studies to find out exactly how much lower the in-
fectivity in the samples is, but based on the survival
time, in vitro-generated PrPres seems to be between 10
and 100 times less infectious than the same quantity of
brain-derived PrPres.
The clinical signs observed in the disease produced
by the amplified samples were identical to those of the
animals inoculated with infectious brain material and
included hyperactivity, motor impairment, head wob-
bling, muscle weakness, and weight loss. In order to
evaluate whether the biochemical and neuropatholog-
ical characteristics of the disease were also the same,
we performed a detailed comparative study of the
brains of animals affected by the disease induced by
brain-derived PrPres (group 5) and PMCA-generated
PrPres (groups 6 and 7). Brain samples from all the
animals in these three groups contained a large and
similar quantity of PrPres, which has an identical gly-
cosylation profile (Figure 6A). Conversely, no protease-
resistant protein was detected in the brains of negative
control animals. To further evaluate whether or not
PMCA-generated infectivity represents a new strain, we
compared the electrophoretic mobility after PK treat-
ment and the glycoform pattern of PrPres with those of
two other standard scrapie strains in hamsters, namely,
263K and drowsy. As shown in Figure 6B, whereas the
Western blot pattern of the PMCA-generated PrPres isidentical to that of 263K (the strain used to produce
new PrPres by PMCA), it is substantially different from
that of drowsy, a strain known to differ biochemically
from 263K.
Histological analysis showed typical spongiform de-
generation of the brain (Figure 6C), and samples from
animals infected with in vitro-produced PrPres showed
a pattern and extent of vacuolation that was indistin-
guishable from those coming from the brains of ham-
sters inoculated with infectious brain material (Figure
S3). The same similarities were also seen when tissue
samples were stained for PrP accumulation (Figure 6D)
and astrogliosis (Figure 6E). Thus, based on all of the
biochemical, histological, and clinical analyses of
the animals, we concluded that in vitro-generated
PrPres triggers a similar neurological disorder as brain-
derived PrPres.
To evaluate whether infectious properties of in vitro-
generated PrPres were stable over time, serial transmis-
sion experiments were done. Brain from one of the
animals inoculated with 10−20 dilution of scrapie brain
homogenate subjected to 16 rounds of PMCA (group 7
in Table 1) was homogenized and injected intraperito-
neally (i.p.) into a group of six wild-type hamsters. All
animals inoculated with this material exhibited typical
signs of the disease with a mean survival time of 136.5
days (Table 2). Hamsters inoculated i.p. with the same
dilution of brain homogenate from an animal originally
infected with brain-derived PrPres (group 5 in Table 1)
developed the disease at 100.2 days postinoculation
(Table 2). No clinical signs were observed in negative
control animals inoculated with normal brain homoge-
nate. All animals in groups 2 and 3 of the experiment in
Table 2 showed protease-resistant PrP in the brain after
postmortem analysis (data not shown). These results
indicate that the infectious agent generated in vitro is
stable over time.
Discussion
Compelling evidence has accumulated over the last
several years in support of the protein-only hypothesis
of prion propagation (Soto and Castilla, 2004; Prusiner,
1998). However, the prion concept is still highly contro-
versial, and it is widely accepted that the final proof for
this hypothesis consists of the generation of infectious
material in vitro by inducing the misfolding of the prion
protein (Soto and Castilla, 2004). Although extensively
attempted, the generation of infectious mammalian pri-
ons in vitro has been elusive. Paradoxically, de novo
generation of infectious proteins has been successfully
done in a simpler system in yeast. A yeast prion has
been defined as an infectious protein that behaves as
a non-Mendelian genetic element, which transmits bio-
logical information in the absence of nucleic acid. Di-
verse genetic, biochemical, and structural evidence
has been provided in support of the prion nature of
the yeast determinants Sup35p and Ure2p (for refer-
ences, see Uptain and Lindquist, 2002). Recent studies
showed that bacterially produced N-terminal fragments
of Sup35p, when transformed into amyloid fibrils, were
able to propagate the prion phenotype to yeast cells
(King and Diaz-Avalos, 2004; Tanaka et al., 2004). Infec-
Cell
202Figure 6. Biochemical and Histopathological
Features of the Disease Induced by Inocula-
tion with PMCA-Generated PrPres
(A) The presence and quantity of PrPres in the
brains of animals in the terminal stage of the
disease produced by inoculation with brain
infectious material (group 5) or with the 1010-
and 1020-fold diluted and amplified material
(groups 6 and 7, respectively) were analyzed
using Western blotting.
(B) The electrophoretic mobility and glyco-
form pattern of PrPres obtained in the ani-
mals inoculated with PMCA-generated PrPres
were compared with the profile of 263K and
drowsy (DY) strains of prions.
(C) Spongiform degeneration was evaluated
after hematoxylin and eosin staining of me-
dulla sections from symptomatic animals in-
oculated with either brain-derived or in vitro-
produced PrPres.
(D) PrP accumulation in these animals was
evaluated by staining the tissue with the 3F4
anti-PrP monoclonal antibody as described
in Experimental Procedures.
(E) Reactive astrogliosis in animals from both
groups was evaluated by histological stain-
ing with glial fibrillary acidic protein anti-
bodies.
For the results shown in this figure, all ani-
mals in groups 5–7 (Table 1) were analyzed,
and the figure corresponds to a representa-
tive picture of these animals. As a control,
brain samples from one animal in group 1
sacrificed without signs of the disease at 280
days after inoculation were used.come close to being the long-awaited definitive proofstrategy consisted of inducing the misfolding of recom-
Table 2. Secondary Transmission of In Vitro-Generated PrPres
Group Experimental Condition Scrapie Brain Dilution Survival Time (Number of Sick/Total Animals)
1 Negative control NBH 2 × 10−2 >200 days (0/6)
2 Positive controla: animals infected 2 × 10−2 100.2 ± 7.7 days (6/6)
with brain PrPres
3 Experimentb: animals infected with 2 × 10−2 136.5 ± 12.9 days (6/6)
PMCA PrPres
The quantity of PrPres inoculated in animals in groups 2 and 3 was similar as evaluated by Western blot. Survival time is expressed as aver-
age ± standard error.
a Animals were inoculated i.p. with 200 l of a 1:50 dilution of brain homogenate from one animal in group 5 in Table 1.
b Animals were inoculated i.p. with 200 l of a 1:50 dilution of brain homogenate from one animal in group 7 in Table 1.tion of yeast with different conformers led to generation b
sof distinct [PSI+] strains in vivo, indicating that differ-
ences in the conformation of the infectious protein de- c
1termine prion strain variation.
Different strategies have been used to attempt the E
tin vitro generation of mammalian prion infectious
material (Soto and Castilla, 2004; May et al., 2004). An p
“approach that has been explored for the purpose of
generating de novo infectivity involved the production h
nof PrP containing mutations associated with inherited
TSEs. Several mutant PrPres-like molecules have been i
egenerated, some of which have been shown to acquire
various biochemical properties of PrPres, but so far, m
enone of them have been shown to be infectious (Leh-
mann and Harris, 1996; Chiesa et al., 1998). Another tinant protein or short PrP synthetic peptides into β
heet-rich structures exhibiting some of the biochemi-
al and biological properties of PrPres (Jackson et al.,
999; Baskakov et al., 2000; Zhang et al., 1995; Lee and
isenberg, 2003). The hope in these experiments was
hat infectivity might be generated even if a very small
ercentage of the protein altered in vitro adopted the
infectious folding.” Unfortunately, these experiments
ave largely failed. Very recently, however, a recombi-
ant mouse PrP fragment (residues 89–230) assembled
nto amyloid fibrils was found to induce a TSE-like dis-
ase with PrPres formation when injected in transgenic
ice overexpressing the same PrP sequence (Legname
t al., 2004). The disease was later transmitted to wild-
ype animals in a second passage. These findings have
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203of the prion hypothesis, but some experimental caveats
remain to be addressed. The fact that the disease was
originally transmitted to transgenic animals largely
overexpressing the PrP gene and not to wild-type ani-
mals is a matter of concern because it is well known
that this type of animals develops a prion-like disease
spontaneously (Westaway et al., 1994; Castilla et al.,
2004a; Chiesa et al., 1998). In other words, the effect
seen might just be an acceleration of the disease pro-
cess that was set to occur spontaneously at a later
time. In this sense, an important missing control was
the inoculation of animals in a second passage with
brain homogenate of transgenic mice not injected with
synthetic prions. Finally, the clinical and histopathologi-
cal presentation of the disease was different from the
usual disease in mice. The authors argued that this re-
sult may be due to the creation of a new strain of
prions.
A strategy that is regarded as more promising is the
generation of infectivity by in vitro conversion of PrPC
because in these experiments the transformation pro-
cess is triggered, catalyzed, and templated by brain-
derived PrPres. The cell-free conversion system devel-
oped by Caughey and coworkers (Kocisko et al., 1994)
uses purified PrPC mixed with stoichiometric amounts
of purified PrPres. The low yield of PrPres formation re-
sulting from this system and the nonphysiological con-
ditions used had made it difficult to evaluate the biolog-
ical and structural properties of the newly converted
protein. However, Collinge and coworkers took advan-
tage of the species-barrier phenomenon to test infec-
tivity of newly generated PrPres under conditions in
which the PrPres from the inoculum would not be infec-
tious (Hill et al., 1999). The results of these experiments
argued that cell-free-generated PrPres was not infec-
tious. A recent study attempting to analyze infectivity of
PMCA-generated PrPres produced inconclusive results
(Bieschke et al., 2004). The most likely reason for this
was that the level of PrPres produced in vitro was still
not high enough to have a clear separation from the
infectivity of the material used to generate the mis-
folded protein. In addition, an important control experi-
ment analyzing the parallel effect of the sonication pro-
cedure on brain-derived infectivity was missing. We
have obtained similar results in other infectivity studies
in which animals inoculated with PrPres obtained after
a low level (10- to 50-fold) of amplification led to incon-
clusive results regarding the infectivity of newly gener-
ated protein (data not shown). However, in experiments
in which a higher level of amplification (>200-fold) was
obtained in a single round of PMCA, a significant in-
crease in infectivity was observed (data not shown).
In this study we have further optimized the PMCA
procedure to reach very high levels of PrPres conver-
sion. Furthermore, we have been able to serially amplify
PrPres in vitro indefinitely. As a result of many rounds of
PMCA following serial dilution of brain infectious
material, we have been able to generate large quanti-
ties of newly synthesized PrPres in the absence of any
molecules of the brain-derived misfolded protein. This
in vitro-generated PrPres isoform has identical bio-
chemical and structural properties to the protein used
to begin the conversion, and, more importantly, the
in vitro-generated PrPres is clearly associated with in-fectivity. Our results represent the first time in which
prion infectious material has been generated in vitro to
produce an in vivo disease in wild-type animals with
characteristics identical to the disease produced by
brain-isolated prions. These results provide some of the
strongest evidence in support of the prion hypothesis.
The fact that a given quantity of in vitro-generated
PrPres is associated with a lower degree of infectivity
as compared with brain-derived infectious material may
explain the inconclusive results from Bieschke and co-
workers (Bieschke et al., 2004) and our own previous
data using a low level of amplified material for inocula-
tion. The reason for the lower level of infectivity in
PMCA-produced PrPres is unknown and currently under
investigation, but we can envision at least three possi-
bilities. First, although the samples contained the same
amount of PrPres as analyzed by Western blot after
SDS-PAGE, the protein molecules might have been or-
ganized into a different number of infectious units. For
example, a large production of PrPres in vitro may have
led to the formation of big aggregates that might be
less efficient for propagating infectivity in vivo, or soni-
cation may have produced too small aggregates that
were not very efficient in maintaining infectivity. Sec-
ond, it is possible that in vitro-generated and in vivo-
derived infectious agents may contain different propor-
tions of resistant and sensitive forms of PrP. In our
biochemical quantitation we only take PrPres into ac-
count. Third, we may have generated a different prion
strain after repeated in vitro amplification reactions. Al-
though the biochemical, histological, and clinical char-
acteristics of the disease produced by in vitro-gener-
ated PrPres were identical to the disease originating
from brain-derived infectious material, the extended in-
cubation periods, both in the first and second pas-
sages, support a possible new strain. Additional experi-
ments of serial transmission and titration are needed to
reach definitive conclusions.
A central facet of the prion hypothesis is that prion
replication is a cyclical process and that newly pro-
duced PrPres can further propagate protein misfolding;
in this way, prions can continue replicating across ani-
mals and generations. Our results show that this pro-
cess of autocatalytic generation of PrPres can be mim-
icked in vitro by PMCA, indicating that prions can be
“cultured” in vitro indefinitely, thus enabling the de-
tailed study of their properties. In vitro-produced PrPres
exhibited properties strikingly similar to those of the
protein isolated from scrapie-affected animals, includ-
ing secondary structure, Western blot profile, protease
resistance, detergent insolubility, resistance to denatur-
ation by heat and chaotropic agents, aggregation into
rod-like structures, efficiency in inducing the misfolding
of the normal PrPC, and in vivo infectivity. These find-
ings indicate that PMCA is a valuable tool for studying
the molecular basis of prion conversion and the factors
involved in this process as well as for identifying novel
compounds that inhibit this pathological event. PMCA
might also be useful for studying the mechanism of the
species barrier and assessing whether the nature of the
prion strains is indeed encoded on the structure of the
misfolded protein. Finally, the high levels of amplifica-
tion resulting from our improved and automated PMCA
procedure may have important applications for TSE di-
Cell
204tagnosis by allowing the highly sensitive detection of
tPrPres.
DExperimental Procedures
S
ePreparation of Tissue Homogenates
3Healthy and sick animals were perfused with phosphate-buffered
fsaline (PBS) plus 5 mM EDTA previous to harvesting the tissue.
aTen percent brain homogenates (w/v) were prepared in conversion
vbuffer (PBS containing 150 mM NaCl, 1.0% Triton X-100, 4 mM
qEDTA, and the complete™ cocktail of protease inhibitors [Boeh-
tringer Mannheim, Mannheim, Germany]). The samples were clari-
sfied by a brief low-speed centrifugation (1500 rpm for 30 s) using
han Eppendorf (Hamburg, Germany) centrifuge, model 5414.
s
sPrPres Purification
One gram of brain tissue was homogenized in 5 ml of cold PBS
Pcontaining protease inhibitors. For PMCA-generated PrPres, the to-
Ptal sample was processed after the last amplification in the same
away as brain homogenate. The samples were mixed with 1 volume
eof 20% sarkosyl, and the mixture was homogenized and sonicated
auntil a clear preparation was obtained. Samples were centrifuged
tat 5000 rpm for 15 min at 4°C. The pellet was discarded, the super-
(natant was mixed with 1/3 volume of PBS containing 0.1% SB-314,
and samples were centrifuged in a Biosafe Optima MAX ultracentri-
Pfuge (Beckman Coulter, Fullerton, California) at 100,000 × g for 3 hr
Pat 4°C. The supernatant was discarded and the pellet was resus-
Apended in 600 l of PBS containing 0.1% SB-314 and 10% NaCl
cand sonicated. The resuspended pellet was layered over 600 l of
dPBS containing 20% saccharose, 10% NaCl, and 0.1% SB-314 and
tcentrifuged for 3 hr at 4°C. The supernatant was discarded and the
spellet was resuspended in 300 l of PBS containing 0.1% SB-314
mand sonicated again. After sonication the samples were incubated
3with PK (100 g/ml) for 2 hr at 37°C and shaken. The digested
Ssample was layered over 100 l of PBS containing 20% sarkosyl,
b0.1% SB-314, and 10% NaCl and centrifuged for 1 hr 30 min at
W100,000 × g. The final pellet was resuspended in 100 l of PBS and
sonicated. The sample was stored at −80°C. Purity was analyzed
Fby silver staining and amino acid composition analysis.
S
mPMCA Procedure
aAlthough the principle of PMCA remains the same as in our original
fpublication (Saborio et al., 2001), the system has been optimized
sand automated, thus enabling the routine processing of many more
ssamples at the same time and reaching a higher conversion effi-
aciency. The detailed protocol, including troubleshooting, has been
drecently published elsewhere (Castilla et al., 2004b; Saá et al.,
t2004). Aliquots of normal and scrapie brain homogenate prepared
rin conversion buffer were mixed and loaded onto 0.2 ml PCR tubes.
TTubes were positioned on an adaptor placed on the plate holder of
ta microsonicator (Misonix Model 3000, Farmingdale, New York) and
programmed to perform cycles of 30 min incubation at 37°C fol-
Elowed by a 40 s pulse of sonication set at 60% potency. Samples
Swere incubated, without shaking, immersed in the water of the son-
bicator bath.
b
wProtease-Resistance Assay
4The profile of PK sensitivity for in vitro- and in vivo-generated
PrPres was studied by subjecting samples to incubation for 60 min
Pat 45°C with different concentrations of PK ranging from 0 to 10,000
Eg/ml. The digestion was stopped by adding electrophoresis sam-
dple buffer. For all other experiments involving PK digestion, the
dstandard conditions used consisted of incubating the samples with
a50 g/ml of the enzyme for 60 min at 45°C.
b
tPrPres Quantification
gPrPres concentration was estimated by Western blotting followed
by densitometric analysis, using known concentrations of hamster
recombinant PrPC (Prionics Inc, Zurich, Switzerland). To obtain a I
Sreliable and robust quantification, we ran several different dilutions
of the sample in the same gel as the standard, thus avoiding arti- a
rfacts due to saturation of the signal or to too weak a signal. In some
selected samples, quantification was confirmed by single ELISA aechnique after PK digestion, using plates coated with 3F4 an-
ibody.
etergent Solubility Assay
amples containing brain homogenate and in vitro- or in vivo-gen-
rated PrPres were incubated in the presence of 10% sarkosyl for
0 min at 4°C. Thereafter, samples were centrifuged at 100,000 × g
or 1 hr in a Biosafe Optima MAX ultracentrifuge (Beckman Coulter),
nd the pellet of the centrifugation was then resuspended in con-
ersion buffer plus electrophoresis sample buffer. Equivalent ali-
uots of supernatant and pellet were analyzed using immunoblot-
ing. In some experiments, prior to the addition of sarkosyl,
amples were incubated with different concentrations of guanidine
ydrochloride for 2 hr at room temperature and shaken. Thereafter,
arkosyl was added and the soluble and insoluble proteins were
eparated using centrifugation.
rPres Detection
roteins were fractionated by sodium dodecyl sulfate-polyacryl-
mide gel electrophoresis (SDS-PAGE) under reducing conditions,
lectroblotted into nitrocellulose membrane, and probed with 3F4
ntibody (Kascsak et al., 1987) (dilution 1:5000). The immunoreac-
ive bands were visualized by enhanced chemiluminescence assay
Amersham, Piscataway, New Jersey).
rotein Deglycosylation Assay
rPres samples were first digested with PK as described above.
fter addition of 10% sarkosyl (final concentration), samples were
entrifuged at 100,000 × g for 1 hr at 4°C, the supernatant was
iscarded, and the pellet was resuspended in 100 l of glycopro-
ein denaturing buffer (New England Biolabs, Beverly, Massachu-
etts) and incubated for 10 min at 100°C. Thereafter, 26 l of 50
M sodium phosphate (pH 7.5) containing 1% nonidet P-40 and
l of peptide N-glycosidase F (New England Biolabs) was added.
amples were incubated for 2 hr at 37°C, the reaction was stopped
y adding electrophoresis buffer, and samples were analyzed by
estern blot.
ourier Transform Infrared Spectroscopy
olutions or suspensions containing highly purified PrPres (5 mg/
l) were prepared in PBS. Two hundred microliters was loaded into
n infrared cell, and samples were dried for 30 min under a nitrogen
low. Spectra were recorded with a Bruker (Billerica, Massachu-
etts) model 66v/S FTIR spectrophotometer at 25°C. For each
pectrum, 512 scans were collected with a 2 cm−1 resolution and
1 cm−1 interval from 4000–700 cm−1. Smoothing and Fourier self-
econvolution were applied to increase the spectral resolution in
he amide I region (1700–1600 cm−1), and iterative fitting to lo-
entzian line shapes was carried out using the Grams software from
hermo Corporation (San Jose, California) to estimate the propor-
ion of each secondary-structure element.
lectron Microscope
amples of PrPres either highly purified from the brain or generated
y PMCA amplification were resuspended in PBS, placed onto car-
on formvar-coated 300-mesh nickel grids, and stained for 60 s
ith 2% uranyl acetate. Grids were analyzed using a Philips EM
10 (FEI Company, Hillsboro, Oregon) electron microscope at 60 kV.
rPres Thermal Inactivation
quivalent samples of brain homogenates containing in vivo-
erived and PMCA-generated PrPres were incubated for 20 min at
ifferent temperatures (room temperature, 100°C, 110°C, 120°C,
nd 140°C). Thereafter, aliquots were taken, diluted into normal
rain homogenate, and subjected to PMCA amplification. Forma-
ion of new PrPres was monitored using Western blot after PK di-
estion.
n Vivo Infectivity Studies
yrian golden hamsters were used. Animals were 4 to 6 weeks old
t the time of inoculation. Anesthesized animals were injected ste-
eotaxically in the right hippocampus with 1 l of the sample using
computerized perfusion machine that delivered the sample into
Production of Prion Infectivity In Vitro
205the brain at a rate of 0.1 l/min. For the second-passage experi-
ments, animals were inoculated i.p. with 100 l of the material. The
onset of clinical disease was measured by scoring the animals
twice per week using the following scale: 1, normal animal; 2, mild
behavioral abnormalities, including hyperactivity and hypersensi-
tivity to noise; 3, moderate behavioral problems, including tremor
of the head, ataxia, wobbling gait, head bobbing, irritability, and
aggressiveness; 4, severe behavioral abnormalities, including all of
the above plus jerks of the head and body and spontaneous back-
rolls; 5, terminal stage of the disease, in which the animal lies in
the cage and is no longer able to stand up. Animals scoring level 4
for two consecutive weeks were considered sick and were sacri-
ficed to avoid excessive pain using exposure to carbonic dioxide.
Brains and other tissues were extracted and analyzed histologi-
cally. The right cerebral hemisphere was frozen and stored at −70°C
for biochemical examination of PrPres using Western blot analysis;
the left hemisphere was fixed in 10% formaldehyde solution, cut
into sections, and embedded in paraffin. Serial sections (6 m
thick) from each block were stained with hematoxylin and eosin,
using standard protocols or incubated with monoclonal antibodies
recognizing PrP or the glial fibrillary acidic protein. Immunore-
actions were developed using the peroxidase-antiperoxidase
method, following manufacturer specifications. Antibody specific-
ity was verified by absorption.
Supplemental Data
Supplemental Data include three figures and one reference and are
available with this article online at http://www.cell.com/cgi/
content/full/121/2/195/DC1/.
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